Mereo Biopharma Group Plc current report, Q2 FY2019

Full document

Business Context and Reporting Period

This Form 6-K filing by Mereo Biopharma Group Plc ("Mereo") covers the month of April 2019, specifically dated April 23, 2019. The primary purpose of the filing is to announce the completion of the merger with OncoMed Pharmaceuticals, Inc. ("OncoMed"), which was originally announced on December 5, 2018. Following stockholder approval on April 17, 2019, and the effective filing of the certificate of merger with the Delaware Secretary of State, OncoMed became a wholly-owned indirect subsidiary of Mereo. The filing also notes that preliminary financial results for the fiscal year ended December 31, 2018, are scheduled for publication on April 29, 2019.

Key Financial Metrics and Capital Structure

The filing does not provide specific revenue, profit, cash flow, or margin figures for the period, as the preliminary results for the 2018 fiscal year are pending publication. However, the document details significant changes to the company's capital structure resulting from the merger:

  • Share Issuance: Mereo issued 24,783,320 new ordinary shares to facilitate the merger.
  • American Depositary Shares (ADS): 4,956,664 ADSs (each representing five new shares) were delivered to former OncoMed stockholders, expected to trade on Nasdaq under the ticker "MREO" starting April 24, 2019.
  • Ownership Dilution: The new shares represent approximately 25.8% of the enlarged issued share capital.
  • Total Share Capital: Following the issuance, the aggregate total ordinary share capital is 96,023,592 shares of £0.003 each.
  • Liquidity: Management commentary states the merger has "strengthened our cash position," though specific cash balance figures are not disclosed in this text.

Material Changes Versus Prior Period

The most significant material change is the consolidation of OncoMed into Mereo, expanding the company's asset base and pipeline. Key changes include:

  • Pipeline Expansion: Mereo added two new product candidates from OncoMed: Navicixizumab (ovarian cancer) and Etigilimab (solid tumors).
  • Board Composition: Michael Wyzga and Deepa Pakianathan, Ph.D., former directors of OncoMed, were appointed as non-executive directors of Mereo.
  • Market Listing: The company initiated an ADR program on the Nasdaq Global Market while maintaining its existing listing on the AIM (London Stock Exchange).
  • Contingent Liability/Asset: Etigilimab is part of a prior collaboration with Celgene. If Celgene exercises its option to obtain an exclusive license, Mereo (via OncoMed) is eligible to receive a $35 million opt-in payment.

Guidance, Outlook, and Risks

Outlook and Management Commentary: CEO Dr. Denise Scots-Knight highlighted that the merger broadens the asset base and enables further progress on rare disease programs. The company anticipates several key data points in 2019:

  • BPS-804 (Osteogenesis Imperfecta): Initial 6-month data from the Phase 2b study expected in Q2 2019; 12-month data expected in Q4 2019.
  • MPH-966 (Alpha-1 Antitrypsin Deficiency): Data from the Phase 2 dose-ranging study expected around the end of 2019.
  • BCT-197 (COPD): Partnering discussions are progressing following a successful FDA Type B meeting.
  • Navicixizumab and BGS-649: Partnering discussions are intended to be initiated in parallel with regulatory interactions.
Risks and Contingencies: The filing includes standard forward-looking statement disclaimers. Specific risks identified include:
  • Failure to realize anticipated benefits of the merger.
  • Unanticipated costs or liabilities associated with the merger.
  • Delays or failures in research and development programs.
  • Availability of sufficient resources to conduct planned clinical development.
  • Outcome of legal proceedings related to the merger.
  • Ability to correctly estimate operating expenses and future cash utilization.

Important Facts for Investor Verification

  • Pending Financials: Verify the preliminary financial results for the year ended December 31, 2018, when published on April 29, 2019, to confirm the specific impact on cash position and debt levels.
  • Trading Status: Confirm the admission of new shares to trading on AIM and the commencement of ADS trading on Nasdaq under ticker "MREO" on April 24, 2019.
  • Celgene Option: Monitor the status of Celgene's option to license Etigilimab, which could result in a $35 million payment to the company.
  • Clinical Milestones: Track the release of Q2 2019 data for BPS-804 and end-of-year data for MPH-966 as critical value drivers.
  • Shareholder Dilution: Note that the merger resulted in the new shares representing approximately 25.8% of the total enlarged share capital.